Comparison of the EGFR Resistance Mutation Profiles Generated by EGFR-targeted Tyrosine Kinase Inhibitors and the Impact of Drug Combinations

Biochemical Journal- United Kingdom

doi 10.1042/bj20080728

Full Text

Abstract

Available in

Date

September 25, 2008

Authors

Egle Avizienyte

Richard A. Ward

Andrew P. Garner

Publisher

Portland Press Ltd.

Related search

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology

English

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Cancer Research

Oncology

2017

English

Hitting the Target: Measuring EGFR Response to Tyrosine Kinase Inhibitors

Cancer Biology and Therapy

English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

HGF Induces Novel EGFR Functions Involved in Resistance Formation to Tyrosine Kinase Inhibitors

English

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology

English

597 EGFR Monoclonal Antibodies and EGFR Tyrosine Kinase Inhibitors Have Distinct Effects on the Keratinocyte Innate Immune Response

Journal of Investigative Dermatology

English

MA27.07 Lung Adenocarcinoma Harboring BRAF G469V Mutation Is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology

English

Amanote Research

Comparison of the EGFR Resistance Mutation Profiles Generated by EGFR-targeted Tyrosine Kinase Inhibitors and the Impact of Drug Combinations

Biochemical Journal- United Kingdom

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Hitting the Target: Measuring EGFR Response to Tyrosine Kinase Inhibitors

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

HGF Induces Novel EGFR Functions Involved in Resistance Formation to Tyrosine Kinase Inhibitors

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

597 EGFR Monoclonal Antibodies and EGFR Tyrosine Kinase Inhibitors Have Distinct Effects on the Keratinocyte Innate Immune Response

MA27.07 Lung Adenocarcinoma Harboring BRAF G469V Mutation Is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors